HCM
FOLD

Highbridge Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Highbridge Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-38,900
Closed -$279K – 1367
2017
Q1 		$279K Buy
+38,900
New +$246K ﹤0.01% 1176
2015
Q1 		– Sell
-25,300
Closed -$210K – 1449
2014
Q4 		$210K Buy
+25,300
New +$174K ﹤0.01% 1052

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Highbridge Capital Management's FOLD Position: Q4 2016 in Review

Highbridge Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 24,757 shares — an estimated $184K sold.

Highbridge Capital Management first reported a position in FOLD in Q2 2014 and held it in 6 quarters. The position peaked at $3.98M in Q2 2015. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

  • Highbridge Capital Management reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 24,757 Amicus Therapeutics shares in Q4 2016, an estimated $184K.
  • Highbridge Capital Management first reported a position in Amicus Therapeutics in Q2 2014 and held it in 6 quarters.
  • Highbridge Capital Management's Amicus Therapeutics position peaked at $3.98M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.